Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | SLC16A3 | O15427 | 10/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butylamine SCHEMBL28683015 | 0.84 | FOLH1 (0.53) | FOLH1SLC16A3TSHR | |
| SCHEMBL27684775 | 0.83 | MEN1 (0.39) | FOLH1SLC16A3TSHR | |
| SCHEMBL28442298 | 0.83 | FOLH1 (0.51) | FOLH1SLC16A3DHODHTSHRALDH1A1 | |
| SCHEMBL7677984 | 0.81 | TSHR (0.54) | TSHRALDH1A1ALOX15LMNA | |
| SCHEMBL31474045 | 0.80 | FOLH1 (0.70) | FOLH1SLC16A3DHODHHMGB1TSHR | |
| SCHEMBL729909 | 0.80 | FOLH1 (0.70) | FOLH1SLC16A3DHODHHMGB1TSHR | |
| Hydrochloric Acid SCHEMBL7749576 | 0.80 | TSHR (0.53) | TSHRALDH1A1ALOX15LMNA | |
| SCHEMBL28750589 | 0.80 | FOLH1 (0.50) | FOLH1HMGB1TSHRALDH1A1ALOX15 | |
| SCHEMBL27718504 | 0.80 | FOLH1 (0.59) | FOLH1SLC16A3TSHRALDH1A1ALOX15 | |
| SCHEMBL6445972 | 0.80 | FOLH1 (0.59) | FOLH1SLC16A3HMGB1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052509-A1 | Calcilytic compounds and method of use | SMITHKLINE BEECHAM CORPORATION | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052509-A1 | Calcilytic compounds and method of use | SOST, CALCR, PTH1R | FOLH1 510/4885SLC16A3 1339/4885DHODH 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.